Abstract: The invention concerns a method for creating, identifying, and isolating ribozymes capable of binding a selected ligand and catalyzing a reaction involving the selected ligand. The method entails sequential selections for ligand binding molecules and catalytic molecules. The invention also includes novel ribozymes produced by these methods.

Abstract: The claimed invention is drawn to a recombinant plasmid which can replicate in Bacillus subtilis, Escherichia coli, and lactic acid Streptococcus bacteria comprising the replication of origin from Streptococcus cremoris plasmid pWV01 as its origin of replication, in addition to coding marker genes and genes of interest which code for improved fermenting properties.

Abstract: Particularly suitable expression vectors for the synthesis of proteins in the fission yeast Schizosaccharomyces pombe (S. pombe) are described. These expression vectors are (in addition to other advantageous elements, equipped with a strong homologous promoter and terminator).

Abstract: Enzymatic RNA molecules which cleave rel A mRNA.

Abstract: A diagnostic or control composition is useful to characterize or control insects and comprises a nucleotide sequence coding for juvenile hormone esterase (JHE). The coding sequence may be combined with a promoter sequence regulating the transcription thereof in a recombinant expression vector for use in controlling insects having a juvenile hormone esterase dependency. Preferred embodiments of the invention are recombinant baculoviruses in which a mutated JHE coding sequence provides relatively rapid speed of kill in insects.

Abstract: The present invention relates to methods and compositions for the treatment of cancer using an oligonucleotide and an hydroxyl radical up-regulator. The oligonucleotide is characterized by its ability to down-regulate the path by which the cell repairs oxidative damage to its DNA. Thus, the oligonucleotide renders the tumor cells more susceptible to eradication upon exposure to the hydroxyl radical up-regulator administered substantially concomitantly with or subsequent to administration of the oligonucleotide. This novel treatment, preferentially inhibits the proliferation or kills malignant cells but not normal cells. Preferably, the oligonucleotide is antisense to the gene which encodes protein p53, although other antisense oligonucleotides can also be used. The invention also includes novel conjugates of the oligonucleotide and the hydroxyl up-regulator, as well as new oligonucleotides.

Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of promyelocytic leukemia.

Abstract: Methods and compositions are provided for producing and utilizing nucleic acid and peptide sequences associated with cofactors which bind to transcription factors to enhance transcriptional activity of the transcriptional factors and maintain the transcriptional factors as dimers. The compositions can be used for modulating expression of genes, particularly coordinately regulated genes, as evidenced by the combination of the transcription factors HNF-1.alpha. and -1.beta. with the cofactor DCoH.

Abstract: Enzymatic RNA molecules which cleave IL-5 mRNA.

Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.

Abstract: A method for preparing foreign protein in yeast using an expression recombinant DNA comprising DNA encoding the serum albumin signal peptide adjacent to DNA encoding the foreign protein is disclosed.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant.Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: Fusion proteins comprise a first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the TYA gene of the yeast retrotransposon Ty. The second amino acid sequence is biologically active; for example it may be antigenic. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.

Abstract: L-tryptophan is produced by constructing a recombinant DNA composed of a vector DNA and DNA fragments bearing all of genetic information relating to the synthesis of DS, AS, PRT, PRAI, InGPS, TS and PGDH, introducing the recombinant DNA into a microorganism belonging to the genus Corynebacterium or Brevibacterium, culturing the microorganism in a medium, and recovering L-tryptophan accumulated in the culture.

Abstract: A recombinant DNA molecule comprising the Streptomyces gal operon galK gene; galE gene; galT gene; P1 promoter; P2 promoter; P2 promoter expression unit; P1 promoter regulated region; or the entire Streptomyces gal operon.

Abstract: A novel method that allows introduction of unidirectional deletions into cloned DNA is described. This method is based on the use of a mixture of oligodeoxynucleotide primers that have fixed 5' (or 3') ends defining the end point of the deletion and variable 3' (or 5') ends composed of mixtures of all four nucleotides at six positions. The 5' ends of the oligodeoxynucleotides are hybridized to a fixed location of the M13K11RX templates and the 3' ends are hybridized randomly to the DNA to be analyzed. Such oligodeoxynucleotide primers when extended with DNA polymerase can direct deletions of intervening parts of the single-stranded DNA that by design contains multiple Eco K sites; the deletion products are selected on a host strain with the Eco K restriction system (e.g., using JM101 cells). This method is an efficient way of generating a nested set of deletion mutants useful for dideoxy-sequencing. It can also be used for creating a set of deletion mutants with a particular codon at the 5' or 3' end point.

Abstract: Yeast promoters of glycolytic enzymes are modified by isolating a fragment encompassing the RNA polymerase binding site and joining to the 5' end of this fragment a DNA sequence providing for enhanced inducible or constitutive transcription of a structural gene. Constructs are prepared for efficient expression of foreign genes in yeast.Yeast strains 2150-2-3(pC1/1GAPSOD) and AB110(pC1/1GAPATi9), producing human .alpha..sub.1 -antitrypsin and superoxide dismutase, were deposited at the A.T.C.C. on May 9, 1984 and given Accession Nos. 20708 and 20709, respectively; and 2150-2-3(GAP5), 2150-2-3(Pyk5) and 2150-2-3(PHO5GAP1), expressing Hepatitis B surface antigen, were deposited at the A.T.C.C. on May 9, 1984 and given Accession Nos. 20705, 20706 and 20707, respectively.

Abstract: Transformed yeasts comprising DNA which include at least one copy of a fragment coding for a 1,4-.beta.-N-acetylmuramidase which is expressed in the yeasts as the corresponding active protein, and a process for preparing lysozyme by growing said transformed yeasts.

Abstract: The present invention relates to the .beta.-glucuronidase (GUS) gene fusion system, and to the cloning and characterization of the .beta.-glucuronidase and glucuronide permease genes of Escherichia coli. It is based on the surprising discovery that gene fusions comprising the .beta.-glucuronidase gene may be effectively expressed in a wide variety of organisms to produce active .beta.-glucuronidase enzyme. Because of the abundance and availability of useful substrates for .beta.-glucuronidase enzyme, GUS gene fusions may serve as a superior reporter gene system as well as an effective means of altering cellular phenotype. In conjunction with recombinant glucuronide permease, which may be used to render host cells permeable to .beta.-glucuronidase substrates, the GUS gene fusion system offers almost unlimited applications in the fields of plant and animal genetic engineering.

Abstract: A precursor of a C-terminal amidated peptide represented by the general formula P-X-Gly-Y.sub.n, wherein P is a peptide residue. X is an amino acid residue the C terminal of which (on the Gly side) can be converted in vivo to a --CONH.sub.2 group. Gly is a glycine residue, Y is a basic amino acid residue, n is an interger of 2 to 4 and a further amino acid residue other than Y or a peptide residue may be attached to Y.sub.n, is produced by a gene engineering technology. The precursor exhibits in vivo physiological activity like the C-terminal amidated peptide.